Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5203570
Max Phase: Preclinical
Molecular Formula: C38H62N6O10
Molecular Weight: 762.95
Associated Items:
ID: ALA5203570
Max Phase: Preclinical
Molecular Formula: C38H62N6O10
Molecular Weight: 762.95
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCCOC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](OCc2ccccc2)[C@@H]1N=[N+]=[N-])C(N)=O
Standard InChI: InChI=1S/C38H62N6O10/c1-4-5-6-7-8-9-10-11-12-13-14-18-23-51-31(46)22-21-29(35(39)48)42-36(49)26(2)41-37(50)27(3)53-34-32(43-44-40)38(54-30(24-45)33(34)47)52-25-28-19-16-15-17-20-28/h15-17,19-20,26-27,29-30,32-34,38,45,47H,4-14,18,21-25H2,1-3H3,(H2,39,48)(H,41,50)(H,42,49)/t26-,27+,29+,30+,32+,33+,34+,38-/m0/s1
Standard InChI Key: MEDBZYOMKRUINI-OCBRUXQYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 762.95 | Molecular Weight (Monoisotopic): 762.4527 | AlogP: 4.23 | #Rotatable Bonds: 28 |
Polar Surface Area: 244.50 | Molecular Species: ACID | HBA: 11 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: -10.30 | CX Basic pKa: | CX LogP: 4.63 | CX LogD: 4.51 |
Aromatic Rings: 1 | Heavy Atoms: 54 | QED Weighted: 0.03 | Np Likeness Score: 0.63 |
1. Reddy PRS, Sambyal S, Mhamane TB, Sravanthi V, Shafi S, Khan IA, Sampath Kumar HM.. (2022) Synthesis and biological evaluation of novel 2-azido muramyl dipeptide as NOD2 agonistic adjuvants., 66 [PMID:35569249] [10.1016/j.bmc.2022.116781] |
Source(1):